CG Oncology, Inc. (CGON)
NASDAQ:CGON
Want to see CGON full AI Analyst Report?
CGON Stock Chart & Stats
$73.43
-$0.55(-1.77%)
At close: 4:00 PM EST
$73.43
-$0.55(-1.77%)
Day’s Range― - ―
52-Week Range$21.00 - $73.56
Previous Close$30.46
Volume740.02K
Average Volume (3M)1.52M
Market Cap
$5.72B
Enterprise Value$5.65B
Total Cash (Recent Filing)$742.15M
Total Debt (Recent Filing)$7.02M
Price to Earnings (P/E)―
Beta1.54
Next Earnings
May 07, 2026EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.08
Shares Outstanding84,435,200
10 Day Avg. Volume1,330,244
30 Day Avg. Volume1,517,357
Financial Highlights & Ratios
PEG Ratio-0.42
Price to Book (P/B)4.26
Price to Sales (P/S)794.47
P/FCF Ratio-24.23
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue1.40K
Enterprise Value/Gross Profit-9.30K
Enterprise Value/Ebitda-33.75
Forecast
1Y Price Target
$90.33Price Target Upside23.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-2.4
Revenue Forecast (FY)$21.54M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And DurabilityConsistent signals of durable cancer control and a favorable safety profile across earlier studies support the potential for long-lasting recurrence reduction and broader clinical adoption.
Pivotal Trial Design And EnrollmentA randomized pivotal late-stage trial with broad patient inclusion and expedited enrollment improves the chance of generating clear, registrational-quality recurrence data that could drive valuation upside.
Regulatory PathwayA rolling biologics license application and expedited review designations could streamline the approval process and increase the likelihood of a commercial launch if regulatory inspections and manufacturing steps are successfully completed.
Bears Say
Comparator And Real-world ApplicabilityAbsence of a chemotherapy or head-to-head immunotherapy control in the trial makes it harder to demonstrate superiority to commonly used standards and may limit clinician uptake even with positive results.
Financing And Market SkepticismNotable cash burn and elevated short interest indicate potential financing needs and investor skepticism that could amplify share volatility around clinical or regulatory setbacks.
High Efficacy Benchmark RiskManagement's defined clinical benchmark raises expectations that, if not met, could trigger investor disappointment and significant downside pressure on the stock.
CG Oncology, Inc. News
CGON FAQ
What was CG Oncology, Inc.’s price range in the past 12 months?
CG Oncology, Inc. lowest stock price was $21.00 and its highest was $73.56 in the past 12 months.
What is CG Oncology, Inc.’s market cap?
CG Oncology, Inc.’s market cap is $5.72B.
When is CG Oncology, Inc.’s upcoming earnings report date?
CG Oncology, Inc.’s upcoming earnings report date is May 07, 2026 which is tomorrow.
How were CG Oncology, Inc.’s earnings last quarter?
CG Oncology, Inc. released its earnings results on Feb 27, 2026. The company reported -$0.55 earnings per share for the quarter, beating the consensus estimate of -$0.6 by $0.05.
Is CG Oncology, Inc. overvalued?
According to Wall Street analysts CG Oncology, Inc.’s price is currently Undervalued.
Does CG Oncology, Inc. pay dividends?
CG Oncology, Inc. does not currently pay dividends.
What is CG Oncology, Inc.’s EPS estimate?
CG Oncology, Inc.’s EPS estimate is -0.56.
How many shares outstanding does CG Oncology, Inc. have?
CG Oncology, Inc. has 84,435,200 shares outstanding.
What happened to CG Oncology, Inc.’s price movement after its last earnings report?
CG Oncology, Inc. reported an EPS of -$0.55 in its last earnings report, beating expectations of -$0.6. Following the earnings report the stock price went up 4.794%.
Which hedge fund is a major shareholder of CG Oncology, Inc.?
Currently, no hedge funds are holding shares in CGON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CG Oncology, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$90.33 (23.02% Upside)
$90.33 (23.02% Upside)
Blogger Sentiment
Bullish
CGON Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 44.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 4.1%
Last 30 Days ▲ 4.1%
News Sentiment
Very Bullish
Bullish news 80%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Positive
20 days / 200 days
Momentum
255.76%
12-Months-Change
Fundamentals
Return on Equity
-22.87%
Trailing 12-Months
Asset Growth
4.87%
Trailing 12-Months
Company Description
CG Oncology, Inc.
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
CGON Stock 12 Month Forecast
Average Price Target
$90.33
▲(23.02% Upside)
Technical Analysis
Cogent Biosciences
―
IDEAYA Biosciences
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Disc Medicine
―
Ownership Overview
10.37% Insiders
26.04% Mutual Funds
1.54% Other Institutional Investors
47.64% Public Companies and
Individual Investors